Publication at Faculty of Medicine in Hradec Králové |
2010
Abstract
There has been a considerable progress in the treatment of chronic lymphocytic leukemia (CLL) during last 10 years. Purine analogs and monoclonal antibodies have enables the switch from purely palliative treatment to intensive regimens which induce complete remissions and may possibly prolong overall survival.
Despite this success, relapse of CLL is inevitable and all patients will eventually become refractory to treatment. This article reviews the recent advances and future possibilities in the treatment of CLL.